For: | McCormack MD, Wahedna NA, Aldulaimi D, Hawker P. Emerging role of dual biologic therapy for the treatment of inflammatory bowel disease. World J Clin Cases 2023; 11(12): 2621-2630 [PMID: 37214562 DOI: 10.12998/wjcc.v11.i12.2621] |
---|---|
URL: | https://www.wjgnet.com/2307-8960/full/v11/i12/2621.htm |
Number | Citing Articles |
1 |
Michael Colwill, Samantha Baillie, Richard Pollok, Andrew Poullis. Using clinical cases to guide healthcare. World Journal of Clinical Cases 2024; 12(9): 1555-1559 doi: 10.12998/wjcc.v12.i9.1555
|
2 |
Kate Lee, Violet Tu, Adam Faye. Optimal Management of Refractory Crohn’s Disease: Current Landscape and Future Direction. Clinical and Experimental Gastroenterology 2024; : 75 doi: 10.2147/CEG.S359376
|
3 |
Puo-Hsien Le, Chien-Ming Chen, Chia-Jung Kuo, Ming-Yao Su, Cheng-Tang Chiu, Yung-Kuan Tsou. Dual Biologic Therapy for Refractory Crohn's Disease With Perforation in a Patient Declining Surgical Intervention. ACG Case Reports Journal 2023; 10(11): e01203 doi: 10.14309/crj.0000000000001203
|
4 |
Christina M. Ray, Remo Panaccione, Christopher Ma. A practical guide to combination advanced therapy in inflammatory bowel disease. Current Opinion in Gastroenterology 2024; doi: 10.1097/MOG.0000000000001033
|
5 |
Giammarco Mocci, Antonio Tursi, Francesca Maria Onidi, Paolo Usai-Satta, Giovanni Mario Pes, Maria Pina Dore. Ustekinumab in the Treatment of Inflammatory Bowel Diseases: Evolving Paradigms. Journal of Clinical Medicine 2024; 13(5): 1519 doi: 10.3390/jcm13051519
|